New name for Humalog insulin biosimilar

Admelog (insulin lispro) is a biosimilar of the rapid-acting insulin Humalog.

Admelog (insulin lispro) is the first biosimilar of a rapid-acting insulin. | SANOFI

Previously marketed as Insulin Lispro Sanofi, Admelog is a 100iu/ml solution for injection available in the SoloStar pre-filled pen, as 3ml cartridges for the AllStar Pro and JuniorSTAR reusable pens, and in a vial for administration by syringe, intravenous injection or infusion pump.

As a biosimilar of Humalog, Admelog has a similar pharmacokinetic and pharmacodynamic profile to the originator product, with a rapid onset of action (approximately 15 minutes) and a shorter duration of activity (2–5 hours) than regular insulin.

Admelog produces a similar mean HbA1c reduction to Humalog in both type I and type II diabetes, and has a similar long-term safety and tolerability profile with comparable rates of hypoglycaemic events.

Admelog has 1:1 dose equivalence to Humalog, so no initial dose conversion is required.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in